Chimeric Antigen Receptor Therapy for B-cell Malignancies

We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy refractory CLL patients.

Detalles Bibliográficos
Autores principales: Porter, David L, Kalos, Michael, Zheng, Zhaohui, Levine, Bruce, June, Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2011
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119397/
https://www.ncbi.nlm.nih.gov/pubmed/21716851

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119397/
https://www.ncbi.nlm.nih.gov/pubmed/21716851

Ejemplares similares